BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol 2013;16:1433-42. [PMID: 23363735 DOI: 10.1017/S1461145712001605] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Mills JC, Harman JS, Cook RL, Marlow NM, Harle CA, Duncan RP, Bengtson AM, Pence BW. Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS. J Affect Disord 2017;215:179-86. [PMID: 28340444 DOI: 10.1016/j.jad.2017.03.042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Caraci F, Leggio GM, Salomone S, Drago F. New drugs in psychiatry: focus on new pharmacological targets. F1000Res 2017;6:397. [PMID: 28408985 DOI: 10.12688/f1000research.10233.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
3 Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 2015;11:875-88. [PMID: 25848287 DOI: 10.2147/NDT.S73261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
4 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
5 Zhou XB, Gu JM, Sun MY, Hu XR, Wu SX. Crystal structures of vortioxetine and its methanol monosolvate. Acta Crystallogr E Crystallogr Commun 2015;71:883-5. [PMID: 26396746 DOI: 10.1107/S2056989015012256] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Pitsillou E, Bresnehan SM, Kagarakis EA, Wijoyo SJ, Liang J, Hung A, Karagiannis TC. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression. Mol Biol Rep 2020;47:753-70. [PMID: 31612411 DOI: 10.1007/s11033-019-05129-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
7 Chiu CH, Chyau CC, Chen CC, Lee LY, Chen WP, Liu JL, Lin WH, Mong MC. Erinacine A-Enriched Hericium erinaceus Mycelium Produces Antidepressant-Like Effects through Modulating BDNF/PI3K/Akt/GSK-3β Signaling in Mice. Int J Mol Sci 2018;19:E341. [PMID: 29364170 DOI: 10.3390/ijms19020341] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
8 Pahwa P, Goel RK. Antidepressant-like effect of a standardized hydroethanolic extract of Asparagus adscendens in mice. Indian J Pharmacol 2019;51:98-108. [PMID: 31142945 DOI: 10.4103/ijp.IJP_116_17] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Hossain R, Al-Khafaji K, Khan RA, Sarkar C, Islam MS, Dey D, Jain D, Faria F, Akbor R, Atolani O, Oliveira SMR, Siyadatpanah A, Pereira ML, Islam MT. Quercetin and/or Ascorbic Acid Modulatory Effect on Phenobarbital-Induced Sleeping Mice Possibly through GABAA and GABAB Receptor Interaction Pathway. Pharmaceuticals (Basel) 2021;14:721. [PMID: 34451819 DOI: 10.3390/ph14080721] [Reference Citation Analysis]
10 Gershon ES, Alliey-Rodriguez N, Grennan K. Ethical and public policy challenges for pharmacogenomics. Dialogues Clin Neurosci 2014;16:567-74. [PMID: 25733960 [PMID: 25733960 DOI: 10.31887/dcns.2014.16.4/egershon] [Cited by in Crossref: 8] [Article Influence: 1.3] [Reference Citation Analysis]